Frequently asked questions
BPC-157 TB-500: the questions, answered from the record
Direct answers on the Wolverine blend — what the constituent studies establish, what they don't, and where the regulatory and safety lines fall.
Definition and combination
What is the Wolverine peptide blend?
A research-community name for a two-peptide pairing of BPC-157 and TB-500, discussed as a tissue-repair "stack" [1]. It is not a single chemical entity or an approved product, and it has no molecular weight or CAS number of its own [1].
What is BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein, supplying a cytoprotective and angiogenic signal [1]. TB-500 is a synthetic acetylated heptapeptide (Ac-LKKTETQ) corresponding to the actin-binding region of Thymosin Beta-4, supplying a cytoskeletal and cell-migration signal [5].
What is the difference between BPC-157 and TB-500?
BPC-157 is a 15-amino-acid pentadecapeptide acting as a local cytoprotective and angiogenic signal; TB-500 is a 7-amino-acid acetylated fragment of Thymosin Beta-4 acting as a cytoskeletal and cell-migration signal [5]. They differ in size, sequence, origin, and mechanism, and only TB-500 derives from a larger endogenous protein [4].
What is the BPC-157 and TB-500 blend used for in research?
It is studied in animal models for tissue repair: BPC-157 in tendon, ligament, muscle, and wound-healing models [1], and TB-500/Thymosin Beta-4 in wound, ligament, and cell-migration models [4]. There is no approved human indication for the blend [13].
Why are BPC-157 and TB-500 combined (the Wolverine stack)?
They are described as acting through complementary but largely non-overlapping pathways: BPC-157 supplies a local angiogenic and cytoprotective signal via VEGFR2-Akt-eNOS [2], and TB-500 supplies an actin-sequestration signal driving cell migration [3]. This "synergy" is a theoretical extrapolation; no controlled combination study has demonstrated it [1].
Evidence and mechanism
Are there human clinical trials on the BPC-157 + TB-500 combination?
No. No controlled clinical trials of the BPC-157 + TB-500 combination exist for any indication, and no peer-reviewed combination preclinical study defines a synergy ratio, dose, or endpoint [1]. Human data exist only for the individual constituents and are themselves thin [8].
Is there any study showing BPC-157 and TB-500 work better together (synergy)?
No. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two peptides given together [1]. The 2025 systematic review of BPC-157 makes no mention of TB-500 or combination use; synergy claims are extrapolations from each peptide's separate mechanism [6].
What is the latest research on BPC-157 and TB-500?
Recent 2024–2026 literature includes a 2025 systematic review of BPC-157 (36 studies, 1 human, "no clinical safety data") [6], a 2026 Sports Medicine narrative review of musculoskeletal peptides [7], a 2025 narrative review calling BPC-157 investigational [8], and 2024–2025 BPC-157 animal studies [9].
What do doctors and reviews say about the BPC-157 + TB-500 blend?
Recent reviews describe BPC-157 as showing preclinical promise but resting on level IV–V evidence with no clinical safety data, and recommend treating it as investigational [6]. Reviews of unapproved musculoskeletal peptides note scarce human safety data and potential for serious harm [7]. None documents a controlled combination study [1].
How does BPC-157 work compared to TB-500?
BPC-157 acts through VEGFR2-Akt-eNOS angiogenic and nitric-oxide signaling and growth-hormone-receptor sensitization of tendon fibroblasts [2]; TB-500 acts through G-actin sequestration and cytoskeletal remodeling [3]. The two are described as complementary, non-overlapping mechanisms [2].
How does TB-500 work (actin / Thymosin Beta-4)?
TB-500's LKKTETQ motif binds monomeric (G-) actin 1:1 and sequesters it, regulating the cytoskeletal dynamics that drive cell migration, re-epithelialization, and progenitor mobilization [3]. Most efficacy data attributed to TB-500 were actually generated with full-length Thymosin Beta-4 [4].
Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?
Both are reported to promote angiogenesis by distinct routes in animal and cell models: BPC-157 via VEGFR2-Akt-eNOS up-regulation [2], and TB-500/Thymosin Beta-4 via endothelial migration [4]. This shared vascular thread is part of the combination rationale.
Dosage, half-life, and handling
What is the half-life of BPC-157 and TB-500?
No validated human half-life exists for either constituent at research-use doses, and none for the blend [1]. BPC-157 elimination half-life was reported under 30 minutes in a rat/dog pharmacokinetic study; no specific half-life is established for the TB-500 heptapeptide [1].
How do you reconstitute a BPC-157 / TB-500 blend (10mg)?
Both constituents are supplied as lyophilized powders reconstituted in bacteriostatic or sterile water and refrigerated for research handling [1]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. This is research-handling context, not human-use guidance.
How often should you inject BPC-157 and TB-500?
There is no validated injection schedule for the blend. Community "loading then maintenance" protocols have no controlled-trial basis [6]. The underlying animal studies used widely varying doses and schedules per compound, and the blend has no peer-reviewed dose-finding study [4].
Safety and the tumor signal
What are the side effects of BPC-157 and TB-500?
Human safety data are limited: BPC-157 has only three small pilot studies, and the TB-500 fragment has no completed controlled human trials [8]. The combination's safety is unproven, and a tumor and angiogenesis signal for Thymosin Beta-4 is a documented concern [4].
Does TB-500 cause cancer or promote tumor growth?
Thymosin Beta-4 is overexpressed in several cancers and has been implicated in metastasis and tumor angiogenesis; the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression [4]. This is a key safety consideration, not a demonstrated effect of the blend in humans [6].
Legal and regulatory
Are BPC-157 and TB-500 FDA approved or banned by WADA?
Neither is FDA-approved for human use, and the blend has no approved indication [13]. Both are prohibited by WADA: BPC-157 under the S0 non-approved-substances category and TB-500 / Thymosin Beta-4 under prohibited peptide and growth-factor categories [7].
Is Wolverine legal?
Neither constituent of the Wolverine blend is FDA-approved, and both are FDA 503A Category 2 substances as of September 29, 2023 — flagged for significant safety risks and outside the Category 1 enforcement-discretion policy [13][14]. Both are also WADA-prohibited in sport [7]. The full picture is set out in the Wolverine legal status and FDA 503A category; this is a description of status, not legal advice.
Can you get BPC-157 from a compounding pharmacy?
BPC-157 is currently an FDA 503A Category 2 substance, not eligible for routine 503A compounding while that status stands [13]. Lawful compounding generally requires a licensed-prescriber evaluation and a valid prescription, with the ingredient eligible under the 503A/503B rules [14]. No pharmacy or provider is named here.
What is the FDA 503A status of Wolverine?
Both constituents of the Wolverine blend are FDA 503A Category 2 bulk drug substances, effective with FDA's September 29, 2023 update [13]. Both are on the agenda of the July 23–24, 2026 PCAC meeting as substances being considered for the 503A bulks list — a scheduled discussion, not a decision [15].